Skip to main content

Table 1 Baseline characteristics

From: Efficacy and safety of erenumab in women with a history of menstrual migraine

  History of Menstrual Migraine
Placebo
N = 83
Erenumab 70 mg
N = 68
Erenumab 140 mg
N = 81
All Patients
N = 232
Age, years, median (range) 37 (20–49) 38 (21–50) 37 (19–50) 37 (19–50)
Race, n (%)
 White 71 (86) 61 (90) 77 (95) 209 (90)
 Black or African American 3 (4) 5 (7) 2 (3) 10 (4)
 Asian 4 (5) 0 (0) 2 (3) 6 (3)
 Other 5 (6) 2 (3) 0 (0) 7 (3)
Migraine with aura,a n (%) 48 (58) 35 (52) 38 (47) 121 (52)
Migraine without aura,a n (%) 71 (86) 61 (90) 72 (89) 204 (88)
Received hormonal contraception, n (%) 20 (24) 18 (26) 27 (33) 65 (28)
Treatment with migraine-preventive medication, n (%)
 Naïve 50 (60) 37 (54) 48 (59) 135 (58)
 Prior and/or concomitant use 33 (40) 31 (46) 33 (41) 97 (42)
Baseline phase (4 weeks)
 Monthly migraine days, mean (SD) 8.6 (2.8) 8.3 (2.4) 8.4 (2.4) 8.4 (2.5)
 Monthly acute migraine-specific medication days, mean (SD) 3.2 (3.5) 3.1 (3.1) 3.7 (3.6) 3.3 (3.4)
 Acute migraine-specific medication use, n (%) 48 (58) 38 (56) 51 (63) 137 (59)
  1. aBased on self-report; categories are not mutually exclusive
  2. Abbreviations: SD standard deviation